COSCIENS BIOPHARMA INC (CSCI.CA) Stock Earnings & Estimates
Canada - Toronto Stock Exchange - TSX:CSCI - CA22112H1010 - Common Stock
3 CAD
+0.2 (+7.14%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | ||
|---|---|---|---|---|
| Revenue YoY % growth | 5.6M 5.66% | 7.143M 27.55% | 9.587M 34.22% | |
| EBITDA YoY % growth | -15.06M -76.14% | -3.186M 78.84% | -12.416M -289.70% | |
| EBIT YoY % growth | -15.2M -74.71% | -4.629M 69.55% | -14.023M -202.94% | |
| Operating Margin | -271.43% | -64.80% | -146.27% | |
| EPS YoY % growth | -11.76 -92.16% | -13.64 -15.99% | N/A 74.80% |
All data in USD
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2024 Q2Q % growth | 80.88% | -0.89 | % | |
| Q3 2024 Q2Q % growth | 73.90% | -0.89 | % | |
| Q2 2024 Q2Q % growth | 59.79% | -0.84 | % | |
| Q1 2024 Q2Q % growth | 76.53% | -0.83 | % | |
| Q4 2023 Q2Q % growth | -4.64 -33.33% | -3.96 | -0.68 | -17.24% |
| Q3 2023 Q2Q % growth | -3.40 -21.43% | -2.49 | -0.91 | -36.61% |
| Q2 2023 Q2Q % growth | -2.08 40.23% | -3.55 | 1.47 | 41.40% |
| Q1 2023 Q2Q % growth | -3.52 -76.00% | -4.37 | 0.85 | 19.37% |
| Q4 2022 Q2Q % growth | -3.48 -74.00% | -3.79 | 0.31 | 8.29% |
| Q3 2022 Q2Q % growth | -2.80 -180.00% | -2.77 | -0.03 | -0.92% |
| Q2 2022 Q2Q % growth | -3.48 | -2.77 | -0.71 | -25.43% |
| Q1 2022 Q2Q % growth | -2.00 | -2.04 | 0.04 | 1.96% |
| Q4 2021 Q2Q % growth | -2.00 | -2.04 | 0.04 | 1.96% |
| Q3 2021 Q2Q % growth | -1.00 | -2.04 | 1.04 | 50.98% |
| Q3 2019 Q2Q % growth | -2.00 | -17.34 | 15.34 | 88.47% |
| Q2 2019 Q2Q % growth | 1.00 | -14.28 | 15.28 | 107.00% |
| Q1 2019 Q2Q % growth | -27.00 | 4.08 | -31.08 | -761.76% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | 1.483M -20.74% | % | ||
| Q2 2025 Q2Q % growth | 2.749M 17.63% | % | ||
| Q1 2025 Q2Q % growth | 1.5M -27.08% | % | ||
| Q4 2024 Q2Q % growth | 3.322M 2,645.45% | 1.122M | 2.2M | 196.08% |
| Q3 2024 Q2Q % growth | 1.871M | 1.122M | 749K | 66.76% |
| Q2 2024 Q2Q % growth | 2.337M 3.87% | 1.122M | 1.215M | 108.29% |
| Q1 2024 Q2Q % growth | 2.057M -3.43% | 1.122M | 935K | 83.33% |
| Q4 2023 Q2Q % growth | 121K -95.14% | 121K | % | |
| Q3 2023 Q2Q % growth | -100.00% | 2.346M | -2.346M | -100.00% |
| Q2 2023 Q2Q % growth | 2.25M 1,122.73% | 1.163M | 1.087M | 93.47% |
| Q1 2023 Q2Q % growth | 2.13M 40.13% | 918K | 1.212M | 132.03% |
| Q4 2022 Q2Q % growth | 2.49M -28.24% | 1.081M | 1.409M | 130.34% |
| Q3 2022 Q2Q % growth | 1.86M 77.14% | 1.362M | 498K | 36.56% |
| Q2 2022 Q2Q % growth | -220K -113.92% | 1.336M | -1.556M | -116.47% |
| Q1 2022 Q2Q % growth | 1.52M -8.98% | 754.8K | 765.2K | 101.38% |
| Q4 2021 Q2Q % growth | 3.47M 46.41% | 639.54K | 2.83M | 442.58% |
| Q3 2021 Q2Q % growth | 1.05M 707.69% | 612K | 438K | 71.57% |
| Q2 2021 Q2Q % growth | 1.58M 2,157.14% | % | ||
| Q1 2021 Q2Q % growth | 1.67M 53.21% | % | ||
| Q4 2020 Q2Q % growth | 2.37M 11,750.00% | % | ||
| Q3 2020 Q2Q % growth | 130K -53.57% | % | ||
| Q2 2020 Q2Q % growth | 70K -63.16% | % | ||
| Q1 2020 Q2Q % growth | 1.09M 2,625.00% | % | ||
| Q3 2019 Q2Q % growth | 280K | 248.88K | 31.12K | 12.50% |
| Q2 2019 Q2Q % growth | 190K | 229.5K | -39.5K | -17.21% |
| Q1 2019 Q2Q % growth | 40K | 4.284M | -4.244M | -99.07% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A |
| Revenue | N/A | N/A | N/A | N/A |